

Christoph Kornauth

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7392852/publications.pdf>

Version: 2024-02-01

50
papers

1,872
citations

331670
21
h-index

265206
42
g-index

51
all docs

51
docs citations

51
times ranked

3651
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders. <i>Cancer Discovery</i> , 2022, 12, 372-387.	9.4	77
2	T-Cell Large Granular Lymphocyte Leukemia: An Interdisciplinary Issue?. <i>Frontiers in Oncology</i> , 2022, 12, 805449.	2.8	1
3	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. <i>Haematologica</i> , 2021, 106, 2251-2256.	3.5	7
4	Tissue distribution of epirubicin after severe extravasation in humans. <i>Cancer Chemotherapy and Pharmacology</i> , 2021, 88, 203-209.	2.3	2
5	Core-binding factor leukemia hijacks the T-cellâ€prone PU.1 antisense promoter. <i>Blood</i> , 2021, 138, 1345-1358.	1.4	12
6	BH3 profiling identifies ruxolitinib as a promising partner for venetoclax to treat T-cell prolymphocytic leukemia. <i>Blood</i> , 2021, 137, 3495-3506.	1.4	22
7	Secondary basophilic leukemia in Ph-negative myeloid neoplasms: A distinct subset with poor prognosis. <i>Neoplasia</i> , 2021, 23, 1183-1191.	5.3	1
8	Influence of TP53 Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era. <i>Cancers</i> , 2021, 13, 5592.	3.7	9
9	Immune Checkpoint Inhibitor Therapy Induces Inflammatory Activity in the Large Arteries of Lymphoma Patients under 50 Years of Age. <i>Biology</i> , 2021, 10, 1206.	2.8	3
10	Metabolic drug survey highlights cancer cell dependencies and vulnerabilities. <i>Nature Communications</i> , 2021, 12, 7190.	12.8	7
11	High activation of STAT5A drives peripheral T-cell lymphoma and leukemia. <i>Haematologica</i> , 2020, 105, 435-447.	3.5	27
12	RECIL Versus Lugano for Treatment Response Assessment in FDG-Avid Non-Hodgkin Lymphomas: A Head-to-Head Comparison in 54 Patients. <i>Cancers</i> , 2020, 12, 9.	3.7	15
13	ECM Characterization Reveals a Massive Activation of Acute Phase Response during FSGS. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2095.	4.1	14
14	STAT5 is Expressed in CD34+/CD38â€ Stem Cells and Serves as a Potential Molecular Target in Ph-Negative Myeloproliferative Neoplasms. <i>Cancers</i> , 2020, 12, 1021.	3.7	12
15	Podocyte RNA sequencing reveals Wnt- and ECM-associated genes as central in FSGS. <i>PLoS ONE</i> , 2020, 15, e0231898.	2.5	10
16	Treatment Guided By Next Generation Functional Drug Screening Provides Clinical Benefit in Advanced Aggressive Hematological Malignancies: Final Evaluation of the Open Label, Single Arm Exalt Trial. <i>Blood</i> , 2020, 136, 2-4.	1.4	1
17	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. <i>Blood</i> , 2020, 136, 40-41.	1.4	0
18	Dependency on the TYK2/STAT1/MCL1 axis in anaplastic large cell lymphoma. <i>Leukemia</i> , 2019, 33, 696-709.	7.2	40

#	ARTICLE	IF	CITATIONS
19	Diagnostic and Prognostic Value of Soluble Urokinase-type Plasminogen Activator Receptor (suPAR) in Focal Segmental Glomerulosclerosis and Impact of Detection Method. Scientific Reports, 2019, 9, 13783.	3.3	41
20	Transformed mucosa-associated lymphoid tissue lymphomas: A single institution retrospective study including polymerase chain reaction-based clonality analysis. British Journal of Haematology, 2019, 186, 448-459.	2.5	16
21	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	1.4	1
22	Characterizing the Anti-Apoptotic Dependencies of T-Cell Prolymphocytic Leukemia Identifies HDAC and JAK/STAT Pathway Inhibitors As Promising Combination Partners to Augment Bcl-2 Targeted Killing By Venetoclax. Blood, 2019, 134, 807-807.	1.4	2
23	Abstract 2689: High-content imaging and single-cell analysis of drug response ex vivo is predictive of clinical outcome for hematologic cancer patients. , 2019, , .		0
24	Imatinib +/- Brentuximab Vedotin Induces Sustained Complete Remission in Chemotherapy-Resistant Anaplastic Large Cell Lymphoma Expressing PDGFR. Blood, 2019, 134, 4037-4037.	1.4	1
25	Bioimaging of isosteric osmium and ruthenium anticancer agents by LA-ICP-MS. Metallomics, 2018, 10, 388-396.	2.4	29
26	[68Ga]Ga-Pentixafor PET/MRI for CXCR4 Imaging of Chronic Lymphocytic Leukemia. Investigative Radiology, 2018, 53, 403-408.	6.2	45
27	Major response of PNH to an AML chemotherapy protocol. Annals of Hematology, 2018, 97, 1487-1488.	1.8	1
28	Immunohistochemical expression of cereblon and MUM1 as potential predictive markers of response to lenalidomide in extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma). Hematological Oncology, 2018, 36, 62-67.	1.7	12
29	Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells. PLoS ONE, 2018, 13, e0205195.	2.5	19
30	miR-150 downregulation contributes to the high-grade transformation of follicular lymphoma by upregulating FOXP1 levels. Blood, 2018, 132, 2389-2400.	1.4	45
31	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood, 2018, 132, 1936-1950.	1.4	18
32	Aggressive B-cell lymphomas in patients with myelofibrosis receiving JAK1/2 inhibitor therapy. Blood, 2018, 132, 694-706.	1.4	132
33	First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. Blood, 2017, 130, 2499-2503.	1.4	59
34	Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematology, 2017, 4, e595-e606.	4.6	130
35	Targeted inhibition of the MAPK pathway: emerging salvage option for progressive life-threatening multisystem LCH. Blood Advances, 2017, 1, 352-356.	5.2	29
36	Next-Generation Functional Drug Screening for Patients with Aggressive Hematologic Malignancies. Blood, 2017, 130, 855-855.	1.4	0

#	ARTICLE	IF	CITATIONS
37	The Phenotypic Characterization of the Human Renal Mononuclear Phagocytes Reveal a Co-Ordinated Response to Injury. PLoS ONE, 2016, 11, e0151674.	2.5	7
38	Interleukin-6 receptor alpha blockade improves skin lesions in a murine model of systemic lupus erythematosus. Experimental Dermatology, 2016, 25, 305-310.	2.9	16
39	Behavior of platinum(IV) complexes in models of tumor hypoxia: cytotoxicity, compound distribution and accumulation. Metallomics, 2016, 8, 422-433.	2.4	39
40	Prefibrotic Primary Myelofibrosis As an Entity Distinct from Other Philadelphia-Chromosome Negative Myeloproliferative Neoplasms - Data from the Austrian Reclassification Project. Blood, 2016, 128, 4252-4252.	1.4	2
41	Impact of Single or Combined Genomic Alterations of TP53, MYC, and BCL2 on Survival of Patients With Diffuse Large B-Cell Lymphomas. Medicine (United States), 2015, 94, e2388.	1.0	24
42	The diffuse extent of peritubular capillaritis in renal allograft rejection is an independent risk factor for graft loss. Kidney International, 2015, 88, 332-340.	5.2	27
43	Extravasation of Pt-based chemotherapeutics – bioimaging of their distribution in resectates using laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS). Metallomics, 2015, 7, 508-515.	2.4	27
44	Tumor microenvironment in focus: LA-ICP-MS bioimaging of a preclinical tumor model upon treatment with platinum(IV)-based anticancer agents. Metallomics, 2015, 7, 1256-1264.	2.4	42
45	Mineral oil in human tissues, Part II: Characterization of the accumulated hydrocarbons by comprehensive two-dimensional gas chromatography. Science of the Total Environment, 2015, 506-507, 644-655.	8.0	50
46	Mineral oil in human tissues, Part I: Concentrations and molecular mass distributions. Food and Chemical Toxicology, 2014, 72, 312-321.	3.6	77
47	Quantitative bioimaging by LA-ICP-MS: a methodological study on the distribution of Pt and Ru in viscera originating from cisplatin- and KP1339-treated mice. Metallomics, 2014, 6, 1616-1625.	2.4	58
48	Focal segmental glomerulosclerosis is induced by microRNA-193a and its downregulation of WT1. Nature Medicine, 2013, 19, 481-487.	30.7	199
49	Immunohistochemical Detection of the BRAF V600E-mutated Protein in Papillary Thyroid Carcinoma. American Journal of Surgical Pathology, 2012, 36, 844-850.	3.7	177
50	Epithelial-mesenchymal transition in hepatocellular carcinoma. Future Oncology, 2009, 5, 1169-1179.	2.4	287